Suppr超能文献

AOSpine骨(骨骨生物制剂与证据)分类法的制定。

Development of AOSpine BOnE (Bone Osteobiologics and Evidence) Classification.

作者信息

Wang Jeffrey C, Yoon S Tim, Brodke Darrel S, Park Jong-Beom, Hsieh Patrick, Meisel Hans-Joerg, Buser Zorica

机构信息

University of Southern California, Los Angeles, CA, USA.

12239Emory University, Atlanta, GA, USA.

出版信息

Global Spine J. 2020 Oct;10(7):871-874. doi: 10.1177/2192568219880176. Epub 2019 Oct 23.

Abstract

STUDY DESIGN

Classification development.

OBJECTIVES

The aim of our study was to develop a 3-tier classification for the levels of evidence for osteobiologics and provide a description of the principles by which osteobiologics can be evaluated. BOnE (Bone Osteobiologics and Evidence) classification evaluates each osteobiologic based on the available evidence, and if the published evidence is based on clinical, in vivo or in vitro studies.

METHODS

The process of establishing the BOnE classification included 5 face-to-face meetings and 2 web calls among members of the AOSpine Knowledge Forum Degenerative.

RESULTS

The 3 levels of evidence were determined based on the type of data on osteobiologics: level A for human studies, level B for animal studies, and level C for in vitro studies, with level A being the highest level of evidence. Each level was organized into 4 subgroups (eg, A1, A2, A3, and A4).

CONCLUSIONS

The use and the variety of osteobiologics for spine fusion has dramatically increased over the past few decades; however, literature on their effectiveness is inconclusive. Several prior systematic reviews developed by AOSpine Knowledge Forum Degenerative reported low level of evidence primarily due to the high risk of bias, small sample size, lack of control groups, and limited patient-reported outcomes. BOnE classification will provide a universal platform for research studies and journal publications to classify a new or an existing product and will allow for creating decision-making algorithms for surgical planning.

摘要

研究设计

分类法开发。

目的

我们研究的目的是为骨生物制剂的证据水平制定一个三级分类法,并描述评估骨生物制剂的原则。BOnE(骨生物制剂与证据)分类法根据现有证据评估每种骨生物制剂,以及已发表的证据是否基于临床、体内或体外研究。

方法

建立BOnE分类法的过程包括AOSpine退变知识论坛成员之间的5次面对面会议和2次网络电话会议。

结果

根据骨生物制剂的数据类型确定了3个证据水平:A 级用于人体研究,B级用于动物研究,C级用于体外研究,其中A级是最高证据水平。每个级别又分为4个亚组(例如,A1、A2、A3和A4)。

结论

在过去几十年中,用于脊柱融合的骨生物制剂的使用和种类显著增加;然而,关于其有效性的文献尚无定论。AOSpine退变知识论坛此前开展的几项系统评价报告称,证据水平较低,主要原因是存在高偏倚风险、样本量小、缺乏对照组以及患者报告结局有限。BOnE分类法将为研究和期刊发表提供一个通用平台,用于对新产品或现有产品进行分类,并将有助于创建手术规划的决策算法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59f1/7485069/009283ed1e77/10.1177_2192568219880176-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验